自身免疫性胃炎的国际多中心研究:临床特征与胃肿瘤风险新见
这项回顾性国际多中心研究纳入1240例组织学确诊的自身免疫性胃炎患者,中位随访68个月。结果显示胃腺癌发生36例(2.9%),1型胃神经内分泌肿瘤132例(10.6%),且临床表现与肿瘤风险存在地区差异。高龄、肠化生、高胃泌素-17及既往PPI使用与腺癌风险升高相关,幽门螺杆菌根除与神经内分泌肿瘤风险降低相关。
要点
- 自身免疫性胃炎患者胃腺癌风险2.9%,1型胃神经内分泌肿瘤风险10.6%。
- 胃泌素-17>1316 pg/mL与腺癌(OR 15.52)和神经内分泌肿瘤(OR 3.25)风险升高相关。
- 幽门螺杆菌根除与1型胃神经内分泌肿瘤风险降低相关(OR 0.25)。
核心结论
- 自身免疫性胃炎的临床表现和肿瘤风险存在地区差异,提示可能需要区域特异性的随访策略。
研究设计与样本
- 回顾性研究,覆盖欧洲、土耳其、拉丁美洲、美国和日本的8个三级中心,纳入1240例组织学确诊的成人自身免疫性胃炎患者。
主要发现
- 1240例患者中女性与男性比例为2:1,中位年龄59岁(IQR 48-67),中位随访68个月(IQR 36-108)。
- 胃腺癌发生36例(2.9%),1型胃神经内分泌肿瘤发生132例(10.6%)。
- 腺癌粗发病率范围为1.15至1.47/100人年,神经内分泌肿瘤粗发病率范围为0.70至1.62/100人年。
- 拉丁美洲和日本队列未报告新发腺癌。
- 大细胞性贫血在欧洲占45.6%,小细胞性贫血在土耳其占56.1%、拉丁美洲占64.7%;自身免疫共病在拉丁美洲最常见(67.7%)。
关键数值与推荐
- 腺癌相关因素:年龄>65岁(OR 4.50,95%CI 2.18-9.27)、肠化生(OR 1.51,95%CI 1.16-1.97)、胃泌素-17>1316 pg/mL(OR 15.52,95%CI 3.61-66.71)、既往PPI使用(OR 5.74,95%CI 2.13-15.47)。
- 神经内分泌肿瘤相关因素:既往PPI使用(OR 2.69,95%CI 1.12-6.46)、吸烟(OR 2.45,95%CI 1.75-3.42)、肠化生(OR 2.88,95%CI 1.38-6.01)、胃泌素-17>1316 pg/mL(OR 3.25,95%CI 1.42-7.45)。
- 幽门螺杆菌根除与神经内分泌肿瘤风险降低相关(OR 0.25,95%CI 0.07-0.88)。
临床怎么用
- 对自身免疫性胃炎患者应评估年龄、肠化生、胃泌素-17水平及PPI使用史以识别高风险人群。
- 考虑对高风险患者进行胃肿瘤监测,并重视幽门螺杆菌根除。
- 随访策略可能需要结合地区差异进行个体化调整。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 随访时间和诊疗习惯在不同中心间可能存在差异。
- 部分亚组事件数较少,关联估计的置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International comparative data on autoimmune gastritis (AIG) remain limited. OBJECTIVE: We aimed to describe AIG features and quantify the risk of gastric adenocarcinoma and type 1 gastric neuroendocrine tumours (NETs). DESIGN: Retrospective study across eight tertiary centres in Europe, Türkiye, Latin America, the USA and Japan. Adults with histologically confirmed AIG were included. Clinical and follow-up data were collected to estimate adenocarcinoma and NET incidence and associated factors. RESULTS: 1240 patients were included (female:male 2:1; median age 59, IQR 48-67; median follow-up 68 months, IQR 36-108). Macrocytic anaemia predominated in Europe (45.6%), microcytic anaemia in Türkiye (56.1%) and Latin America (64.7%). Autoimmune comorbidities were most frequent in Latin America (67.7%). 36 (2.9%) gastric adenocarcinomas and 132 (10.6%) NETs occurred. No incident adenocarcinomas were reported in Latin America or Japan cohorts. Crude incidence rates ranged from 1.15 to 1.47 for adenocarcinoma and 0.70 to 1.62/100 person-years for NETs. Factors associated with adenocarcinoma included age >65 years (OR 4.50, 95% CI 2.18 to 9.27), intestinal metaplasia (OR 1.51, 95% CI 1.16 to 1.97), gastrin-17 >1316 pg/mL (OR 15.52, 95% CI 3.61 to 66.71) and prior proton pump inhibitor (PPI) (OR 5.74, 95% CI 2.13 to 15.47). For NETs, prior PPI (OR 2.69, 95% CI 1.12 to 6.46), smoking (OR 2.45, 95% CI 1.75 to 3.42), intestinal metaplasia (OR 2.88, 95% CI 1.38 to 6.01) and gastrin-17 >1316 pg/mL (OR 3.25, 95% CI 1.42 to 7.45), were associated with higher odds, while Helicobacter pylori eradication was associated with lower odds of NETs (OR 0.25, 95% CI 0.07 to 0.88). CONCLUSION: AIG presentation and neoplastic risks differ by region, warranting further research and potentially region-specific follow-up strategies.
引用
- Lenti MV, Miceli E, Soykan I, et al. Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre study. Gut. 2026. PMID: 41791849. doi:10.1136/gutjnl-2025-337458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。